#Genmab announces European Marketing Authorization for the #Subcutaneous Formulation of DARZALEX® (#daratumumab) for the Treatment of Patients with Multiple Myeloma

$GMAB $JNJ $HALO

https://t.co/Ds6Dav4lEz